mdna11
Generic: IL-2 Superkine-Recombinant Human Albumin Fusion Protein MDNA11
mdna11: 1 clinical trial tracked.
mdna11 evidence translation
What we can confirm
1 tracked trial
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about mdna11, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (1)
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors
Primary endpoint: MDNA11 Recommended Dose for Expansion for monotherapy (mRDE) and Recommended Dose for Expansion for combination (cRDE)
Interventionalopen160 targetStarted 2021-08Completion 2028-1228 sites · Australia, Canada, Ireland, Portugal…Medicenna Therapeutics, Inc.